In the present study, we observed that promoter hypermethylation of RIZ1 is significantly more frequent in advanced CML disease compared to early disease and is a characteristic feature of poor imatinib respondents. The gene discussed is PRDM2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.